BiotechTube

AOC 1044

Phase 2Active
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

DMD

Conditions

DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44

Trial Timeline

Jan 22, 2024 → Jul 31, 2027

NCT ID
NCT06244082

About AOC 1044

AOC 1044 is a phase 2 stage product being developed by Avidity Biosciences for DMD. The current trial status is active. This product is registered under clinical trial identifier NCT06244082. Target conditions include DMD, Duchenne Muscular Dystrophy, Duchenne.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06244082Phase 2Active

Competing Products

14 competing products in DMD

See all competitors
ProductCompanyStageHype Score
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
RO7239361 + PlaceboRochePhase 1/2
41
DYNE-251 + PlaceboDyne TherapeuticsPhase 1/2
36
AVI-4658 (Eteplirsen)Sarepta TherapeuticsPhase 2
47
eteplirsenSarepta TherapeuticsPhase 2
47
eteplirsenSarepta TherapeuticsPhase 3
72
IV infusionPepGenPhase 2
44
PBGENE-DMD (IV)Precision BioSciencesPhase 1/2
33
idebenone + placeboSanthera PharmaceuticalsPhase 2
44
Idebenone 150 mg film-coated tablets + placeboSanthera PharmaceuticalsPhase 3
69
talfirastideConstant TherapeuticsPhase 2
44

Other Products from Avidity Biosciences

Del-desiran (AOC 1001)Phase 3
74
AOC-1020 + PlaceboPhase 3
74
AOC 1001 (del-desiran) + PlaceboPhase 3
74
Placebo + AOC 1001Phase 2
49
AOC 1020Phase 2
49